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Xavier Catteau1,2*, Philippe Simon2,3 and Jean-Christophe Noël2,4Abstract
Background: The microenvironment modulates tissue specificity in the normal breast and in breast cancer. The
stromal loss of CD34 expression and acquisition of SMA myofibroblastic features may constitute a prerequisite for
tumor invasiveness in breast carcinoma. The aim of the present study is to examine the stromal expression of CD34
and SMA in cases of invasive ductal carcinoma and to try to demonstrate the role played by the TGF-ß 1 et TGF-ß
R1 pathway in the transformation of normal breast fibrocytes into myofibroblasts.
Methods: We carried out an immunohistochemical study of CD34, SMA, TGF-ß and TGF-ß R1 on a series of 155
patients with invasive ductal carcinoma. We also treated a breast fibrocytes cell line with TGF-ß1.
Results: We found a loss of stromal expression of CD34 with the appearance of a myofibroblastic reaction in
almost 100% cases of invasive ductal carcinoma. The strong stromal expression of SMA correlates with the presence
of lymph node metastases. We were also able to show a greater expression of TGF-ß in the tumor cells as well as a
higher expression of TGF- ß R1 in the tumor stroma compared to normal breast tissue. Finally, we demonstrated
the transformation of breast fibrocytes into SMA positive myofibroblasts after being treated with TGF-ß1.
Conclusions: Our study demonstrated that a significant tumor myofibroblastic reaction is correlated with the
presence of lymph node metastasis and that this myofibroblastic reaction can be induced by TGF-ß1. Future
research on fibrocytes, myofibroblasts, TGF-ß and stromal changes mechanisms is essential in the future and may
potentially lead to new treatment approaches.
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Lymph nodeBackground
Breast cancer is the most common cancer among women
in the world [1]. The microenvironment modulates nor-
mal breast tissue, as well as the growth, survival, polarity,
and invasive behavior of breast cancer cells [2,3]. The stro-
mal loss of CD34 expression and acquisition of smooth
muscle actin (SMA) myofibroblastic features may consti-
tute a prerequisite for tumor invasiveness in breast carcin-
oma [4,5]. The origin of myofibroblasts is not yet clear
and multiple hypotheses have been proposed. Myofibro-
blasts modulate the stroma in physiology and pathology* Correspondence: xavier.catteau06@gmail.com
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unless otherwise stated.through direct cell-to-cell contact and through secretion
of different proteinases, extracellular matrix (ECM) com-
ponents, growth factors and cytokines. Transforming
Growth-Beta (TGF-ß) are multifunctional cytokines which
inhibit epithelial cell growth, stimulate mesenchymal cell
proliferation, regulate ECM, modulate immune function
and wound repair. A desmoplastic reaction is frequent in
many solid tumors, such as breast tumors, in which high
levels of TGF-ß are found [6-9]. Casey et al. demonstrated
that TGF-ß1 treatment in vitro activates normal primary
breast fibroblasts and carcinoma-associated fibroblasts
(CAFs) into myofibroblasts [10,11], and subcutaneous in-
jections of TGF-ß1 into mice stimulates the formation of
reactive stroma [12]. We hypothesize that TGF-ß facili-
tates breast cancer invasion by stimulating the appearancel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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motes invasion and facilitates metastasis. The present
study aims to investigate this phenomenon in cases of in-
vasive ductal carcinoma (IDC) and to try to understand
the underlying mechanism responsible for this myofibro-
blastic reaction, especially the role played by TGF-ß.
Methods
Study population
Breast tissue from cancer patients and normal controls
(reduction mammoplasty) was collected from consecutive
patients who were identified through the Pathology and
Genetics Institute (IPG), resulting in 165 consecutive pa-
tients diagnosed between January 2010 and December
2012. This retrospective study was performed on 155 cases
of invasive breast carcinoma and 10 cases of reduction
mammoplasty from normal breast tissue to compare the
expression of the antibodies between the tumor and nor-
mal breast tissue. All patients were female. 83 resection
specimens and 82 biopsies were obtained. The study
protocol was approved by the institutional ethics and re-
search review boards at Erasme Hospital. People sign a
written informed consent on admission to the hospital.
Consent requires that physicians have the right to use the
surplus biological material. The material that has not been
used for diagnosis can be used for research (opting out
system). Consent has been established by the local ethics
committee and is in accordance with Belgian and Inter-
national law (Helsinki declaration). The final pathological
tumor stage was determined using the TNM staging sys-
tem (AJCC Cancer Staging Manual, 7th edition, 2007) and
graded using the Nottingham system [13]. In addition, the
patient’s age, tumor size, tumor shape, estrogen receptor
(ER), progesterone receptor (PR), HER2/Neu status and
KI-67 index were assessed in per cases. Among them, ra-
diologists reviewed the radiological images of tumors and
classified them as nodular, spiculate or mixed lesions.
Cell line cultures
Human mammary fibrocytes P10893 was purchased from
Innoprot® and maintained in Innoprot-recommended
media and conditions. The media were changed every two
days. When cells reached confluence they were passaged
to a 25 cm2 flask (Corning® Plasticware Cell Culture,
Corning, NY, USA) by treating with 0.25% trypsin-25 mM
EDTA (Gibco® Invitrogen Corporation) and agitating until
cells began to detach from the surface of the flask (passage
1; p1). P2 cells were moved to a 75 cm2 flask and then pas-
saged 1:4. All experiments were performed on fibrocytes
that had been cultured for 3–10 passages.
Cells were phenotypically characterized by immuno-
staining. Cells positive for vimentin and negative for cyto-
keratin staining were considered fibroblasts. Cells were
plated in six well chamber slides (Corning®), and grown toconfluence. Cells were washed with PBS and fixed with 4%
buffered formalin and immunostained according to the
manufacturer’s protocols.
Assessment of fibrocytes activation into myofibroblasts
Cells were plated and grown to confluence in six-chamber
slides in basal medium. Media was aspirated from the cul-
tures and cells were washed twice with PBS and then incu-
bated for 24 h in serum-free media with 0 or 2.5 ng/ml
TGF-ß1 (Peprotech®) for 48 h with a change in the culture
medium after 24 h. After 48 h, cells were fixed, and incu-
bated with SMA and CD34 antibodies. The percentage of
myofibroblasts was assessed by counting at least 1,000 total
cells and determining the proportion stained positively for
SMA in three fields at 200X in duplicate preparations.
Immunohistochemistry
The specimens were fixed in histology-grade 4% buff-
ered formalin. Series paraffin sections were stained with
hematoxylin and eosin and immunohistochemical detection
was performed according to the manufacturer’s protocols
(Table 1). We used a fully automated immunohistochemical
system (Autostainer Link 48 from Dako®).
Semi-quantitative assessment of immunohistochemistry
We analyzed the stromal distribution of CD34 and SMA
in the tumor. Immunohistochemical expression of TGF-
ß and transforming growth-Beta receptor-1 (TGF-ßR1)
was evaluated in normal breast tissue (glands and
stroma) and in tumor tissue (tumor cell and stroma).
The immunoreactivity of CD34, SMA, TGF-ß and TFG-
ßR1 was assessed semi-quantitatively. The percentage of
stromal cells expressing CD34 and SMA was graded as
“0”, “+”, “++”, “+++”, “++++” when up to 5%, more than
5% and up to 25%, more than 25% and up to 50%, more
than 50% and up to 75% or more than 75% of stromal
cells, disclosed immunoreactivity, respectively. Percent-
ages were assessed by two independent observers, as-
suming that a high-power microscopic field (objective
x40, microscopic magnification: x400) harbored 100
stromal cells (range: 75–150). We also evaluated the
presence or absence of expression of TGF-ß and TGF-
ßR1 in glands and stroma of normal and tumor tissue.
Staining intensity for the TGF-ß and TGF-ßR1 anti-
bodies was assessed in a semiquantitative manner by XC
and JCN using the H scoring system as described by
McCarty et al. [14]. Briefly, scores are generated by add-
ing together 3 ×% strongly staining, 2 ×% moderately
staining, and 1 ×% weakly staining, giving a possible
range of 0 to 300. An H-score >50 was considered as
positive. An assessment of total percentage of cells
showing positive staining was also carried out. When
disagreements occurred between the two observers they
were resolved using a double-headed microscope.
Table 1 Antibodies used in this study
Antigen Clone Dilution Source Catalog number
CD 34 QBEnd-10 Monoclonal Mouse Ready-to-use Dako IR63261
Vimentine V9 Monoclonal Mouse Ready-to-use Dako IR63061
α-SMA 1A4 Monoclonal Mouse Ready-to-use Dako IR00611
CKAE1/AE3 AE1/AE3 Monoclonal Mouse Ready-to-use Dako IR05361
TGF-ß TGFB17 Monoclonal Mouse 1/20 Vector VP-T486
TGF-ß R1 8A11 Monoclonal Mouse 1/25 Vector VP-T487
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The relationship between the staining patterns of SMA
and different clinical and histological features - age, tumor
size, tumor shape, grade of invasive carcinoma, lymph
node status, luminal classification, and KI-67 index - was
compared using a Chi-squared test. A Student’s t-test was
used to compare H-score and percentage positivity. A p-
value <0.05 was considered statistically significant. All ana-
lyses were performed using Statistica®.
Results
Clinicopathological features of invasive breast
carcinoma patients
This study was performed on 155 cases of IDC. All cases
were female. Their ages ranged from 25–100 years with a
mean age of 61.1 years. Table 2 summarizes the clinical
and histological features of the study population. In all
cases, the peritumoral stroma appeared fibrous (desmo-
plastic) upon routine staining with hematoxylin-eosin.
This fibrosis appeared to be hyaline in 90% of cases and
eosinophilic in 10% of cases. Stromal cells were fusiform,
had spindle-shaped nuclei and did not show nuclear-
cytoplasmic atypia. 65% (101/155) of tumors had a stellar
pattern, 21% (33/155) of tumors a nodular pattern andTable 2 Clinicopathological data of 155 cases of invasive
breast carcinoma
Clinical data No (%)
Tumor size
T1 (0.1- 2 cm) 101 (65)
T2 (>2- 5 cm) 50 (32)
T3 (>5 cm) 4 (3)
Tumor grade*
Grade 1 32 (21)
Grade 2 84 (54)





*The Nottingham system was used to assess tumour grade.14% (21/155) of tumors showed a mixed pattern. When
the cells were organized in nodular pattern, the stroma
between the cells was less visible but was nevertheless
present.
Stromal CD34 and SMA in vivo expression
In normal mammary tissue, muscular blood vessels,
glandular ducts, and acinii were surrounded by a dense
concentric network of CD34 fibrocytes. Slight CD34
staining was noted on small-caliber blood vessels within
the stroma. No CD34 reactivity was observed in epithe-
lial cells. SMA was detected in the wall of muscular ves-
sels and in the myoepithelia lining the ductal and acinar
basement membranes, whereas SMA-reactive myofibro-
blasts were not detected in the stroma of normal breast
tissue (Figure 1). The cancer-associated stromal cells
were SMA-positive, vimentin-positive and cytokeratin-
negative, confirming their identity as myofibroblasts.
Myofibroblasts were found intimately surrounding tu-
moral cells (Figures 2C to E). In all 155 cases of IDC,
the stroma showed a complete loss of CD34 fibrocytes
except around the vessels, while the surrounding mam-
mary tumor-free tissue disclosed a normal distribution
of this cell population (Figures 2A and B). About 97%
(151/155) of IDC revealed SMA myofibroblasts. 78.7%
(122/155) showed a significant to very significant myofi-
broblastic reaction (+++, ++++) while 18.7% (29/155)
showed lowto moderate expression (+, ++). There was a
significant relationship between SMA and LN status.
Strong (+++, ++++) SMA expression was significantly re-
lated to the presence of lymph node metastasis (p <0.05).
No significant relationship was present between SMA ex-
pression and other clinicopathological data (Table 3).
TGF-ß and TGF-ßR1 in vivo expression
Both normal breast ducts (Figure 3A) and tumor epithelial
cells expressed (Figures 3C and D) TGF-ß with higher ex-
pression in tumor cells compared to normal ducts (p =
0.02). We found no expression of TGF-ß in normal breast
tissue and tumor stroma. We found expression of TGF-
ßR1 in normal breast ducts and tumor epithelial cells with
no statistically significant difference (p = 0.4) (Figure 3B and
F). On the other hand, the myofibroblastic stroma of the
tumor expressed more TGF- ßR1 than the normal stroma
Figure 1 CD34 and SMA expression in normal breast tissue. A: normal breast ducts (X100; H&E staining). B: diffuse CD34 expression within
the periductal stroma of normal ducts (X100). C: absence of SMA expression within the periductal stroma of normal ducts (X100).
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in the tumor stroma was present regardless of the level of
expression of TGF-ß by the tumor (Table 4).
In vitro transformation of fibrocytes into myofibroblasts
by TGF-ß1 in mammary cell line fibrocytes
The proportion of myofibroblasts in each culture
treated with 0 or 2.5 ng/ml TGF-ß1 was determined
by counting the number of cells immunostained for
SMA expression. The percentage of myofibroblast var-
ied from 0 to 70% among the normal cultures and cul-
tures with TGF-ß1 treatment causing a noticeable
shift in the percentage of activated myofibroblasts in
many normal and treated cultures (Figure 4). TGF-ß1
treatment significantly increased the mean percentage
of myofibroblasts in cultures (p < 0.05). It should be
noted that the fibrocytes of this cell line do not
express CD34.
Discussion
The importance of changes in the microenvironment
during tumor progression has been increasingly recog-
nized [3,15,16]. We have just demonstrated in this work
the appearance of a myofibroblastic reaction accompan-
ied by a loss of fibrocytes in IDC. This reaction is
present in almost 100% of cases, irrespective of clinical
and histological parameters (age, tumor size, tumor
shape, grade of invasive carcinoma, luminal classifica-
tion and KI-67 index). This phenomenon is therefore al-
most constant and more than likely plays an important
tumoral role, particularly in the invasion process. Fur-
thermore and importantly, this pro-invasive action
seems to be confirmed by the fact that an intense ex-
pression of SMA myofibroblasts was correlated with the
presence of lymph node metastasis. In cancer, myofibro-
blasts may induce the production of proinvasive protein-
ases [17]. We already carried out a study on the stromal
expression of CD34 and SMA in ductal carcinoma in situ
(DCIS) [18]. Our in vitro experiments showed a trans-
formation of fibrocytes into myofibroblasts by TGF-ß1,which is one of the main agents involved in this fibro-
myofibroblastic transformation. Indeed, different stud-
ies have shown that TGF-ß upregulates SMA expres-
sion in fibrocytes and transdifferentiates them into
myofibroblasts [19,20] This in vitro study also showed,
for the first time, that fibrocytes not expressing CD34
are also capable of transforming into myofibroblasts
under the action of TGF-ß1. Indeed, in a previous study,
we thought that only periductal fibrocytes expressing
CD34 were able to transform into SMA myofibroblasts
[21]. In our opinion, the loss of fibrocytes and myofibro-
blast activation does not appear to be just a passive re-
action. We believe they are an integral part of the
process by facilitating tumor progression and tumor in-
vasion. Besides their role in wound healing, myofibro-
blasts provide pro-invasive signals that in combination
affect invasion of the cancer cells [22,23]. The cross-
talk between cancer cells and stromal cells may be me-
diated through direct heterotypic cell-to-cell contact or
through secreted molecules, comprising growth factors,
cytokines, chemokines, extracellular matrix proteins,
proteinases, proteinase inhibitors, and lipid products
[24]. The mechanism leading to the loss of fibrocytes
and the appearance of SMA myofibroblasts in the
stroma of invasive carcinomas is complex and far from
being understood. Breast cancer cells have been shown
to be capable of factor secretion [25]. Therefore, we
speculate that loss of CD34 fibrocytes and gain of SMA
myofibroblasts might be initiated by a soluble factor se-
creted by tumor cells and especially TGF-ß. We have
shown that medium conditioned with TGF-ß1 induces
SMA expression in mammary fibrocytes stromal cell
line. Moreover, some research has already found that
fibrocytes acquire SMA expression when exposed to
TGF-ß [19,21]. Considering the results of the present
study, it appears to be more likely that mammary
fibrocytes acquire SMA having been treated by TGF-
ß1. Indeed, our in vivo study of the immunohisto-
chemical expression of TGF-ß and TGF-ßR1 allowed






Figure 2 Stromal CD34 and SMA expression in invasive ductal carcinoma. A and B: absence of stromal expression of CD 34, except within
invasive ductal carcinoma vessels (X100). C and D: example of weak stromal expression of SMA within invasive ductal carcinoma (C:X40; D:X100).
E and F: example of strong stromal expression of SMA within invasive ductal carcinoma (E:X40; F:X200).
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have TGF-ß receptors. As demonstrated in vitro,
tumor cells are therefore able to transform fibrocytes
into SMA myofibroblasts.
2) Tumor cells may have an autocrine effect on their
growth because they have TGF-ßR1 and
express TFG-ß.
3) Since the stroma does not express TGF-ß, it
therefore seems unlikely that the stroma maytrigger the process of tumorigenesis via the TGF-ß
pathway in any case.
We believe that several mechanisms may explain the
promotion of tumor invasion in breast tissue induced
by the loss of CD34 fibrocytes and the gain of SMA
myofibroblasts.
What are the mechanisms involved in the pro-invasive
capacity of fibrocytes?







≤ 40 7 1 p = 0.9
>40-≤ 60 52 14
> 60 58 16
Grade
Grade 1 27 6 p = 0.98
Grade 2 62 18
Grade 3 33 9
Tumor shape




≤ 1 cm 28 12 p = 0.1
> 1 -≤ 2 cm 42 9
> 2 cm 46 9
KI-67 index
≤ 15% 53 14 p = 0.9
> 15% 59 18
Lymph node status
Metastasis 52 8 p < 0.05
No metastasis 40 16
Significant P value is <0.05.
*Strong expression means that > 50% of stromal cells express SMA (score +++
and ++++). **Weak expression means that < 50% of stromal cells express SMA
(score + and ++).
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cells and might be involved in specific immune
surveillance [26,27].
2) CD34 fibrocytes are involved in the remodeling of
stromal tissue damage not only through tissue
contractility via TGF-ß, collagen I and III synthesis
and SMA, but also in terms of migration factors
within the injured tissue via CCR7, CXCR4, SLC,
and CXCL12.
3) CD34 fibrocytes also play a role in angiogenesis via
fibroblast growth factor, vascular endothelial growth
factor, platelet-derived growth factor, interleukin-8,
and matrix metalloproteinase-9.
What are the mechanisms involved in the pro-invasive
capacity of myofibroblasts?
1) The increase in myofibroblasts in breast cancer
could result from transdifferentiation of residentinterstitial cells expressing or not expressing CD34
fibrocytes into myofibroblasts.
2) Orimo et al. [23] demonstrated that carcinoma-
associated fibroblasts (CAF), represented to a large
degree by myofibroblasts, promote tumor growth and
increase tumor angiogenesis by secretion of stromal
derived factor (SDF)-1/CXCL12, which acts in a
paracrine fashion to increase tumor cell proliferation
via CXCR4. Hepatocyte growth factor (HGF) is
another CAF-derived factor that has been implicated
in promoting tumor progression and metastasis. The
paracrine activation of c-Met on tumor cells by HGF
increases invasion of experimental DCIS lesions in
xenografts, for example [28]. Interestingly, co-culture
of normal mammary fibroblasts with breast cancer
cells can ‘educate’ the fibroblasts to secrete HGF and
increase their tumor-promoting activities [29].
3) The causal role of myofibroblasts in the transition
from the non-invasive towards the invasive
phenotype is suggested by the finding that the
appearance of myofibroblasts precedes the
invasive stage of cancer. This hypothesis seems to
be confirmed in one of our previous studies in
which we demonstrated the appearance of
myofibroblasts around the lesions of DCIS. This
expression was more intense around the
high-grade lesions (pre-invasive lesions) [18].
4) Associated myofibroblasts prevent physical contact
between cancer cells and immune cells, an essential
phenomenon for cancer cell destruction. Histology
of different types of tumors indicates that, in those
tumors in which the myofibroblastic network is
poorly developed, inflammatory cells infiltrate the
tumors and are in close contact with the cancer
cells. In contrast, the presence of myofibroblasts
around progressive tumors is associated with the
absence of immune and inflammatory cells within
tumors [30].
5) In contrast to wound healing, myofibroblasts in the
tumor microenvironment do not disappear by
apoptosis, indicating that cancer is a wound that
does not heal [31].
6) The stromal reaction induced by carcinomatous
lesions leads to acquisition of SMA expression and
in turn to stabilization of the lesion (wound
contraction) that helps prevent the spread of tissue
damage [32]. This may reflect a defense mechanism
against “stromal invasion” that induces a
phenomenon of stromal healing and stabilization.
However, the phenotypic transformation or
suppression of (CD34) fibrocytes into SMA
myofibroblasts could also cause the loss of most
essential functions (including immunity, cell





Figure 3 TGF-ß and TGF-ßR1 expression in normal breast tissue and invasive ductal carcinoma. A: presence of ductal expression of TGF-ß in
normal breast tissue (X100). B: presence of ductal expression of TGF-ßR1 in normal breast tissue (X200). C and D: presence of ductal expression of TGF-ß
within invasive ductal carcinoma (C:X200; D:X100). E and F: presence of stromal expression of TGF-ß R1 within invasive ductal carcinoma (E:X400; F:X100).
Table 4 TGF-ß and TGF-ßR1 expression in tumor and
normal tissue
Tumor tissue Normal tissue
Stromal TGF- ß 0 0 p > 0.05
Glandular TGF- ß 185 + − 81 125 + −41 p = 0.02
Stromal TGF- ß R1 197 + −104 80 + −27 p = 0.001
Glandular TGF- ß R1 129 + −102 110 + −22 p = 0.4
Significant p value is <0.05.
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manner promote tumorigenesis, thus facilitating
invasion and metastatic dissemination of tumor cells.
Conclusions
The present study demonstrated that a significant
tumor myofibroblastic reaction is correlated with the
presence of lymph node metastases and that this myofi-
broblastic reaction can be induced by TGF-ß1. Future
A B
C
Figure 4 CD34 and SMA expression in breast fibrocytes cell line before and after treatment by TGF-ß1. A: absence of an expression of
CD34 within untreated breast fibrocytes (X200). B and C: presence of a significant proportion of SMA-positive myofibroblasts after treatment of
breast fibrocytes by TGF-ß1 (B:X40; C:X400).
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stromal change mechanisms are needed to confirm
these results and may potentially lead to new treatment
approaches.
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